Protector Forsikring ASA (NO0010209331)
XSTU 
Summary
NO0010209331 Chart
Protector Forsikring ASA (NO0010209331) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Protector Forsikring ASA ever had a stock split?
Protector Forsikring ASA Profile
| Biotechnology Industry | Healthcare Sector | Michael Moshe Cohen CEO | XSTU Exchange | US74371C2089 ISIN |
| US Country | 164 Employees | - Last Dividend | 21 Aug 2008 Last Split | - IPO Date |
Overview
Proteonomix, Inc. is a pioneering biotechnology company dedicated to developing innovative therapeutics using human cells and their derivatives. Initially founded as National Stem Cell Holding, Inc., the company underwent a rebranding to Proteonomix, Inc. in August 2008. Since its inception in 1995, Proteonomix has leveraged its proprietary technologies to create a diverse range of products aimed at improving human health and wellness. Based in Hawthorne, New Jersey, Proteonomix is at the forefront of biotechnological research and development, focusing on groundbreaking treatments for a variety of conditions and diseases, as well as anti-aging solutions.
Products and Services
- Proteoderm
- UMK-121
- StromaCel
- NC-138
An innovative anti-aging skin cream, Proteoderm, stands out as Proteonomix, Inc.'s venture into dermatological products. This cream is formulated with a proprietary and patented matrix of proteins specifically designed to reduce wrinkles and revitalize the skin, showcasing the company's expertise in leveraging human cell derivatives for therapeutic applications.
UMK-121 is Proteonomix's therapeutic approach to liver disease, offering a new hope for patients with this condition. It utilizes a novel treatment strategy that combines two or three approved drugs to mobilize specific bone marrow stem cells. This process is aimed at facilitating the regeneration and repair of liver tissue, embodying the company's commitment to cell-based therapy solutions.
StromaCel represents Proteonomix's innovative treatment for cardiac patients, particularly those who have suffered a myocardial infarction within the last two weeks. By using stem cells derived from donor bone marrow and administering them through an IV solution, StromaCel seeks to repair heart tissue. This method demonstrates the company's dedication to advancing stem cell therapy as a viable option for cardiac rehabilitation.
NC-138, another proprietary matrix of proteins developed by Proteonomix, further showcases the company’s focus on skin care and anti-aging products. Like Proteoderm, NC-138 is designed to act on the skin, enhancing activities that reduce wrinkles and promote a more youthful appearance, reaffirming Proteonomix's role in the intersection between biotechnology and dermatology.
